ERBB2 and breast carcinoma: Later, ENHERTU (Trastuzumab, T-DXd) was the first ADC to use the camptothecin derivative Dxd as a payload, successfully achieving targeted therapy against HER2 and showing significant efficacy in HER2-positive breast cancer [5].